Stammdaten
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Unternehmen & Branche
| Name | Transcode Therapeutics, Inc. |
|---|---|
| Ticker | RNAZ |
| CIK | 0001829635 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 7,7 Mio. USD |
| Beta | 1,50 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -34,661,076 | -52.59 | 162,398,689 | 10,335,466 | |
| 2025-09-30 | 10-Q | -4,856,051 | -5.82 | 5,226,682 | 1,425,979 | |
| 2025-06-30 | 10-Q | -4,276,502 | -5.13 | 8,266,410 | 6,147,706 | |
| 2025-03-31 | 10-Q | -12,085,413 | -2.51 | 13,194,375 | 10,292,698 | |
| 2024-12-31 | 10-K | -16,754,971 | -###.## | 7,294,499 | -2,018,734 | |
| 2024-09-30 | 10-Q | -2,321,387 | -146.06 | 3,936,105 | 1,652,165 | |
| 2024-06-30 | 10-Q | -5,190,814 | -680.23 | 4,824,588 | 1,322,274 | |
| 2024-03-31 | 10-Q | -3,326,812 | -21.35 | 7,290,467 | 4,584,295 | |
| 2023-12-31 | 10-K | -18,546,095 | -###.## | 5,169,701 | 1,640,814 | |
| 2023-09-30 | 10-Q | -5,299,962 | -48.44 | 10,227,846 | 4,439,894 | |
| 2023-06-30 | 10-Q | -4,341,653 | -142.38 | 5,881,545 | 2,092,463 | |
| 2023-03-31 | 10-Q | -4,816,934 | -259.07 | 5,590,510 | -236,792 | |
| 2022-12-31 | 10-K | -17,564,968 | -###.## | 7,587,986 | 3,240,696 | |
| 2022-09-30 | 10-Q | -4,289,610 | -6.61 | 12,015,573 | 8,244,197 | |
| 2022-06-30 | 10-Q | -4,671,232 | -7.20 | 14,155,456 | 12,428,205 | |
| 2022-03-31 | 10-Q | -3,470,070 | -0.27 | 18,850,017 | 17,000,838 | |
| 2021-12-31 | 10-K | -6,843,399 | -0.81 | 22,938,443 | 20,404,346 | |
| 2021-09-30 | 10-Q | -2,329,706 | -0.20 | 25,359,852 | 23,155,120 | |
| 2021-06-30 | 10-Q | 2,770,904 | 0.51 | 1,522,265 | -5,036,081 | |
| 2021-03-31 | 10-Q | -4,485,338 | -0.97 | -7,845,139 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.